Download App

Log in to access Online Inquiry
Company Overview More
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
CEO: Mullen, James C.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > EDIT Editas Medicine > Detailed Quotes

EDIT Editas Medicine

10.720-0.910-7.82%
Close 05/18 20:00 ET
10.700-0.02-0.19%
Post Mkt Price 05/18 19:41 ET
High
11.480
Open
11.250
Turnover
15.66M
Low
10.520
Pre Close
11.630
Volume
1.44M
Market Cap
735.83M
P/E(TTM)
Loss
52wk High
73.025
Shares
68.64M
P/E(Static)
Loss
52wk Low
9.710
Float Cap
713.20M
Bid/Ask %
56.52%
Historical High
99.950
Shs Float
66.53M
Volume Ratio
0.84
Historical Low
9.710
Dividend TTM
--
Div Yield TTM
450
P/B
1.44
Dividend LFY
--
Div Yield LFY
4197.76%
Turnover Ratio
2.17%
Amplitude
8.25%
Avg Price
10.855
Lot Size
1
Float Cap
713.20M
Bid/Ask %
56.52%
Historical High
99.950
Shs Float
66.53M
Volume Ratio
0.84
Historical Low
9.710
Dividend TTM
--
P/B
1.44
Dividend LFY
--
Turnover Ratio
2.17%
Amplitude
8.25%
Avg Price
10.855
Lot Size
1
Price Forecast

No Data

News

Comment